My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

uniQure N.V. - Ordinary Shares (NQ:QURE)

30.33 +0.45 (+1.51%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 14, 2025

Via Benzinga

Dow Jones Hits Record as Shutdown Deal Nears—AI Sector Feels the Heat ↗

November 12, 2025

Optimism about a possible end to the U.S. government shutdown pushed the Dow Jones to new highs, but Big Tech couldn’t keep up. Nvidia took a beating after SoftBank’s surprise exit.

Via Chartmill

Topics Stocks

uniQure (QURE) Q3 2025 Earnings Call Transcript ↗

November 10, 2025

uniQure (QURE) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

A Glimpse of uniQure's Earnings Potential ↗

November 07, 2025

Via Benzinga

uniQure Stock Tumbled 56% Today: What’s The FDA Angle? ↗

November 03, 2025

Via Stocktwits

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection ↗

November 05, 2025

Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Blair downgrade.

Via Benzinga

Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Drug ↗

November 05, 2025

The company was nearing approval for a treatment for a rare, neurodegenerative disease. Then, the FDA spoke.

Via Investor's Business Daily

Topics Earnings

Super Micro Computer Posts Downbeat Q1 Results, Joins Pinterest, Axon Enterprise And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

November 05, 2025

Via Benzinga

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗

November 04, 2025

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

Via Benzinga

Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 04, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 04, 2025

Via Benzinga

Why Upwork Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket ↗

November 04, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

November 03, 2025

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Which stocks are moving on Monday? ↗

November 03, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Gold Edges Higher; ISM Manufacturing PMI Falls In October ↗

November 03, 2025

Via Benzinga

UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data ↗

November 03, 2025

UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington's disease, delaying BLA plans.

Via Benzinga

Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗

November 03, 2025

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 03, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

November 03, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Nasdaq Surges 1%; ON Semiconductor Posts Upbeat Q3 Earnings ↗

November 03, 2025

Via Benzinga

Uniqure Plummets 59% On A 'Confusing' And 'Unexpected' Twist For Its Gene Therapy ↗

November 03, 2025

An analyst described the FDA feedback as "confusing" and "unexpected" for the experimental Huntington's disease treatment.

Via Investor's Business Daily

Discover the top movers in Monday's pre-market session. ↗

November 03, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 30, 2025

Via Benzinga

Breakout Momentum Plays You Need to Know About ↗

October 23, 2025

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

Via MarketBeat

Why Is Protalix BioTherapeutics Stock Falling On Friday? ↗

October 17, 2025

EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.